Loading provider…
Loading provider…
Hematology & Oncology Physician in Gainesville, FL
NPI: 1104867365Primary Practice Location
UF HEALTH SHANDS HOSPITAL
4101 Nw 89th Blvd, Gainesville, FL
Primary Employer
UF Health Physicians
ufhealth.org
HQ Phone
Get MD Thomas's Phone Numberphone_androidMobile
Get MD Thomas's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
1999 - 2027

American Board of Internal Medicine
Medical Oncology
University of Florida
Fellowship • Hematology and Medical Oncology
2002 - 2005
Residency • Internal Medicine
1998 - 2002
University Of Florida College Of Medicine
med.ufl.edu
Medical School
Until 1998
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 25 | 32 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 21 | 55 |
| 3 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 12 | 12 |
Authors: Chen, Huan, Butler, Earlesha, Guo, Yi, George, Thomas, Modave, François, Gurka, Matthew, Bian, Jiang
Journal: Health Commun
Publication Date: 2018-02-27
Management of Malignant Bowel Obstruction Associated With GI Cancers.
Authors: Jason Starr, Atif Iqbal, Rajesh Nair, Aaron Franke
Journal: J Oncol Pract
Lead Sponsor: Pancreatic Cancer Action Network
Intervention / Treatment: DRUG: Drug: Dose -SM-88, DRUG: Gemcitabine combined with nab-paclitaxel, DRUG: Dose -mFOLFIRINOX, DRUG: Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, DRUG: Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine
Lead Sponsor: University of Florida
Collaborators: GlaxoSmithKline
Intervention / Treatment: DRUG: Niraparib
Lead Sponsor: NSABP Foundation Inc
Intervention / Treatment: DRUG: durvalumab